Table 4.
Suitability of video consultations compared to face-to-face consultations, association with main reason for contact (new problem/follow up), and the 20 most common issues/presented problems, N=3350.
| Issue/presented problem | Main reason for contact | |||||||
| New problem (n=1484) | Follow-up (n=1866) | |||||||
| Better or same (n=529) | Worse (n=955) | Better or same (n=1140) | Worse (n=726) | |||||
| Contacts, n/N | Proportion, % (95% CI) | Contacts, n/N | Proportion, % (95% CI) | Contacts, n/N | Proportion, % (95% CI) | Contacts, n/N | Proportion, % (95% CI) | |
| Mental illness/life stress | 67/105 | 64 (54-73)a | 38/105 | 36 (28-46)a | 442/579 | 76 (73-80)a | 137/579 | 24 (20-27)a |
| Musculoskeletal problems | 33/183 | 18 (13-24)a | 150/183 | 82 (76-87)a | 154/286 | 54 (48-60) | 132/286 | 46 (40-52) |
| Suspicion of COVID-19 or COVID-19–related | 99/222 | 45 (38-51) | 123/222 | 55 (49-62) | 46/94 | 49 (39-59) | 48/94 | 51 (41-61) |
| Skin disorders | 69/234 | 30 (24-36)a | 165/234 | 71 (64-76)a | 29/66 | 44 (32-56) | 37/66 | 56 (44-68) |
| Children | 52/173 | 30 (24-37)a | 121/173 | 70 (63-76)a | 41/74 | 55 (44-66) | 33/74 | 45 (34-56) |
| Lung | 27/96 | 28 (20-38)a | 69/96 | 72 (62-80)a | 26/87 | 30 (21-40)a | 61/87 | 70 (60-79)a |
| Administrative issues | 45/57 | 79 (67-88)a | 12/57 | 21 (12-33)a | 62/80 | 78 (68-86)a | 18/80 | 23 (14-33)a |
| Gynecology and pregnancy | 24/50 | 48 (35-62) | 26/50 | 52 (38-65) | 39/74 | 53 (41-64) | 35/74 | 47 (36-59) |
| Infection | 25/84 | 30 (21-40)a | 59/84 | 70 (60-79)a | 10/32 | 31 (17-48) | 22/32 | 69 (52-83) |
| Endocrinology | 6/15 | 40 (19-65) | 9/15 | 60 (35-81) | 54/99 | 55 (45-64) | 45/99 | 46 (36-55) |
| Cardiovascular | 2/37 | 19 (9-34)a | 30/37 | 81 (66-91)a | 32/72 | 44 (33-56) | 40/72 | 56 (44-67) |
| Complex issues and disorders | 10/20 | 50 (29-71) | 10/20 | 50 (29-71) | 65/86 | 76 (66-84)a | 21/86 | 24 (16-34)a |
| Gastrointestinal | 12/47 | 26 (15-39)a | 35/47 | 75 (61-85)a | 20/50 | 40 (27-54) | 30/50 | 60 (46-73) |
| ENT (ear, nose, and throat) | 23/68 | 34 (23-46)a | 45/68 | 66 (54-77)a | 12/22 | 55 (34-74) | 10/22 | 46 (26-66) |
| Neurology | 4/20 | 20 (7-41)a | 16/20 | 80 (59-93)a | 39/51 | 77 (64-86)a | 12/51 | 24 (14-36)a |
| Cancer follow-up | 2/3 | 67 (18-96) | 1/3 | 33 (4-82) | 28/41 | 68 (53-81)a | 13/41 | 32 (19-47)a |
| Eye | 12/36 | 33 (20-50)a | 24/36 | 67 (51-80)a | 1/4 | 25 (3-72) | 3/4 | 75 (28-97) |
| Urology | 9/22 | 41 (23-62) | 13/22 | 59 (39-78) | 5/15 | 33 (14-58) | 10/15 | 67 (42-86) |
| Headache | 1/8 | 13 (1-45)a | 7/8 | 88 (55-99)a | 13/25 | 52 (33-71) | 12/25 | 48 (30-67) |
| Intoxication and addiction | 2/4 | 50 (12-88)a | 2/4 | 50 (12-88)a | 22/29 | 76 (58-89)a | 7/29 | 24 (12-42)a |
aNonoverlapping CIs.